ClinicalTrialsFinder
RecruitingNCT07339254

Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

Experiences With and Attitudes Towards Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer (NSCLC) - A Single Center, Survey-Based Study

Sponsor

University of Southern California

Enrollment

40 participants

Start Date

Mar 12, 2026

Study Type

OBSERVATIONAL

Conditions

Lung Non-Small Cell Carcinoma

Summary

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • \* Age ≥ 18 years.
  • \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
  • \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
  • \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.

Exclusion Criteria2

  • \* Patients is unable to consent for themselves
  • \* Patient has not yet completed the 1st cycle of ICI-based therapy

Interventions

OTHERNon-Interventional Study

Non-interventional study

Locations(2)

Los Angeles General Medical Center

Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07339254

Related Trials

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635220 locations

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

NCT06418204467 locations

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NCT042678481149 locations

National Cancer Institute "Cancer Moonshot Biobank"

NCT04314401152 locations

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

NCT066604071 location